Monday, August 18, 2025 8/18/2025

Metabolic control of normal and malignant hematopoiesis

Award Number: R37CA251543
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2020
PERIOD OF PERFORMANCE END DATE: 05/31/2027

Group Awards By:

View Award Description

Metabolic control of normal and malignant hematopoiesis - PROJECT SUMMARY/ABSTRACT Somatic mutations in the isocitrate dehydrogenase (IDH) enzymes contribute to the pathogenesis of acute myeloid leukemia (AML) and other malignancies via production of the ‘oncometabolite’ D-2-hydroxyglutarate (D-2HG). D-2HG blocks differentiation of malignant cells by inhibiting alpha-ketoglutarate (KG)-dependent enzymes that regulate chromatin structure and gene expression. Small molecule inhibitors of mutant IDH enzymes are promising new therapies for AML, but their efficacy remains limited to the subset of patients with IDH mutations. This raises the question as to whether analogous metabolic aberrations might contribute to leukemogenesis in IDH-wildtype AML. Intriguingly, 2HG is a chiral molecule that can exist in either the D- or L- enantiomer. Although cancer-associated IDH mutants exclusively produce D-2HG, biochemical studies indicate that L-2HG can function as a ~10-fold more potent inhibitor of many KG-dependent enzymes, including chromatin modifiers and regulators of hypoxia-inducible factor (HIF) stability. However, biological sources and activities of L-2HG have been poorly understood. We identified a metabolic pathway wherein normal and malignant cells without IDH mutations selectively produce L-2HG in response to oxygen limitation (a.k.a. hypoxia) through an unusual reaction catalyzed by lactate dehydrogenase (LDHA). We show that hypoxia-induced L-2HG enhances stability of HIF, increases repressive chromatin modifications, and blocks differentiation of stem/progenitor cells. These findings suggest that L-2HG might account, at least in part, for the importance of hypoxic niches, HIF, and LDHA in balancing self-renewal and differentiation of stem cell populations, including hematopoietic stem/progenitor cells (HSPC) and leukemia stem cells. Thus, we hypothesize that L-2HG functions as a metabolic signal that couples hypoxic niches to the maintenance of normal blood stem cells and leukemia stem cells. This hypothesis will be rigorously addressed in three Specific Aims. Aim 1 will define the molecular mechanisms by which L-2HG regulates blood cell differentiation in vitro. In this Aim, we will define the effects of L-2HG on gene expression and chromatin structure and determine how these inputs balance HSPC stemness and lineage differentiation. Aim 2 will determine how L-2HG functions to control normal and malignant hematopoiesis in vivo. This Aim will use novel genetically engineered mouse models that allow for tissue-specific, inducible manipulation of L-2HG levels in order to dissect the role of L-2HG in normal hematopoiesis and leukemia. Aim 3 will elucidate the oncogenic mechanisms and therapeutic potential of L-2HG in human leukemia. In this Aim, we will use primary AML biospecimens and patient-derived xenografts to determine the mechanisms that lead to deregulated L- 2HG in a subset of AML and assess whether depleting L-2HG offers a promising strategy to treat human AML. The proposed studies will offer fundamental insights into the metabolic control of normal and malignant stem cell biology and expand the applicability of metabolic targeted therapies for leukemia and other cancers.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $964,128 )
2025	2025	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Biology Research	000	6	7/22/2025	EXTENSION WITH OR WITHOUT FUNDS	$964,128
														Subtotal = $964,128

Issue Date FY: 2024 ( Subtotal = $460,563 )
2024	2024	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVENUE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Biology Research	000	5	5/21/2024	NON-COMPETING CONTINUATION	$460,563
														Subtotal = $460,563

Issue Date FY: 2023 ( Subtotal = $475,107 )
2023	2023	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Biology Research	000	4	5/17/2023	NON-COMPETING CONTINUATION	$475,107
														Subtotal = $475,107

Issue Date FY: 2022 ( Subtotal = $484,803 )
2022	2022	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Biology Research	000	3	6/9/2022	NON-COMPETING CONTINUATION	$484,803
														Subtotal = $484,803

Issue Date FY: 2021 ( Subtotal = $484,803 )
2021	2021	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Biology Research	000	2	5/21/2021	NON-COMPETING CONTINUATION	$484,803
														Subtotal = $484,803

Issue Date FY: 2020 ( Subtotal = $484,803 )
2020	2020	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Biology Research	000	1	8/24/2020	NEW	$484,803
														Subtotal = $484,803

Grand Total All Awards = $3,354,207

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Metabolic control of normal and malignant hematopoiesis

Award Number: R37CA251543

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2020

PERIOD OF PERFORMANCE END DATE: 05/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer